Elanco Animal Health Incorporated $ELAN Shares Purchased by Independent Advisor Alliance

Independent Advisor Alliance boosted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 364.5% in the third quarter, HoldingsChannel.com reports. The fund owned 98,025 shares of the company’s stock after purchasing an additional 76,920 shares during the period. Independent Advisor Alliance’s holdings in Elanco Animal Health were worth $1,974,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Jennison Associates LLC increased its stake in shares of Elanco Animal Health by 322.0% during the second quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after purchasing an additional 2,468,122 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Primecap Management Co. CA increased its stake in Elanco Animal Health by 3.1% during the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after buying an additional 1,543,279 shares in the last quarter. Norges Bank acquired a new position in shares of Elanco Animal Health during the second quarter valued at approximately $12,502,000. Finally, Brandes Investment Partners LP raised its holdings in shares of Elanco Animal Health by 11.3% during the second quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after acquiring an additional 820,901 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were acquired at an average price of $21.30 per share, with a total value of $213,000.00. Following the purchase, the director directly owned 131,773 shares in the company, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were acquired at an average price of $21.75 per share, with a total value of $478,500.00. Following the completion of the acquisition, the chief executive officer owned 167,000 shares in the company, valued at approximately $3,632,250. This trade represents a 15.17% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have purchased 43,450 shares of company stock valued at $937,883. 0.89% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. UBS Group upped their target price on shares of Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 29th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.44.

Elanco Animal Health Trading Up 2.8%

Shares of ELAN stock opened at $24.75 on Tuesday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $25.29. The company’s 50-day moving average price is $23.06 and its 200-day moving average price is $20.46. The stock has a market cap of $12.30 billion, a price-to-earnings ratio of 412.57, a PEG ratio of 3.38 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the firm earned $0.13 earnings per share. Elanco Animal Health’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.